Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02158533 · ClinicalTrials.gov registry record · Phase 3
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 385
- Enrollment target
NCT02158533 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 385 participants.
The verdict
NCT02158533, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 385 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of ALKS 5461.
Interventions
- DRUG Placebo
- DRUG High Dose ALKS 5461
- DRUG Low Dose ALKS 5461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02158533
The ClinicalTrials.gov registry entry for NCT02158533 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02158533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02158533 about?
NCT02158533 is a clinical study titled "A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study". This study will evaluate the efficacy and safety of ALKS 5461.
What is the current status of trial NCT02158533?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 385 participants. The study started on 2014-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02158533?
The interventions under investigation include: Placebo (DRUG), High Dose ALKS 5461 (DRUG), Low Dose ALKS 5461 (DRUG).
Who is sponsoring clinical trial NCT02158533?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.